Clinical Trials on Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Norway

Total 28 results

National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
Seagen Inc.

Completed

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Triple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast Neoplasms

United States
Oslo University Hospital
Bristol-Myers Squibb; Helse Stavanger HF; Sorlandet Hospital HF; Cliniques universitaires... and other collaborators

Completed

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (ICON)

Breast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Tumor

Norway, Belgium
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
University Hospital, Akershus
Vestre Viken Hospital Trust; Novartis

Recruiting

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB)

Breast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast Cancer

Norway
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Oslo University Hospital
Norwegian Cancer Society; Klinbeforsk

Active, not recruiting

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer (EMIT)

Breast Cancer | Breast Neoplasms | Hormone Receptor Positive Tumor

Norway
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage...

United States, South Africa
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Bayer; United States Department of Defense; Canadian...

Terminated

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Node Positive HER2 Negative Breast Cancer

United States, Canada, Puerto Rico, Guam
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor... and other conditions

United States
OncoTherapy Science, Inc.

Recruiting

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
Dompé Farmaceutici S.p.A
PRA Health Sciences

Completed

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)

Metastatic Breast Cancer

United States, Spain, Belgium, Italy, France, Czechia, Poland
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | HER2/Neu Negative | Breast Adenocarcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States, South Africa
Memorial Sloan Kettering Cancer Center

Recruiting

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Non Small Cell Lung Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Recurrent Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Novartis Pharmaceuticals

Completed

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)

United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Seagen Inc.

Recruiting

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States, Canada, Puerto Rico
OncoC4, Inc.
National Cancer Institute (NCI)

Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)

Cervical Cancer | Small Cell Lung Cancer | Adenoid Cystic Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Melanoma | Pancreas Cancer | Metastatic... and other conditions

United States, Australia
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States

Clinical Trials on Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations